Investigating the associations between uncarboxylated matrix gla protein as a proxy for vitamin K status and cardiovascular disease risk factors in a general adult population
2025

Vitamin K Status and Cardiovascular Disease Risk Factors

Sample size: 4092 publication Evidence: moderate

Author Information

Author(s): Lauridsen Julie Aaberg, Leth-Møller Katja Biering, Møllehave Line Tang, Kårhus Line Lund, Dantoft Thomas Meinertz, Kofoed Klaus Fuglsang, Linneberg Allan

Primary Institution: Center for Clinical Research and Prevention, Copenhagen University Hospital, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark

Hypothesis

This study investigates the association between plasma dephospho-uncarboxylated matrix Gla protein (dp-ucMGP) as a proxy for vitamin K status and cardiovascular disease risk factors.

Conclusion

Higher levels of dp-ucMGP are associated with increased risks of central obesity, diabetes, hyperlipidaemia, and impaired kidney function.

Supporting Evidence

  • Higher dp-ucMGP levels were associated with increased risk of central obesity.
  • Higher dp-ucMGP levels were linked to diabetes.
  • Higher dp-ucMGP levels correlated with hyperlipidaemia.
  • Higher dp-ucMGP levels were associated with impaired kidney function.

Takeaway

This study found that people with higher levels of a certain protein related to vitamin K are more likely to have health issues like obesity and diabetes.

Methodology

A cross-sectional population-based health examination study was conducted with 4,092 individuals, assessing vitamin K status using plasma dp-ucMGP and linking participants to health records for medication use.

Potential Biases

Self-reported data may introduce recall bias, and adjustments for treatment effects may not fully account for confounding.

Limitations

The study's cross-sectional design limits causal inference and may be subject to reverse causation.

Participant Demographics

Participants were aged 24–77 years, with a mean age of 59.4 years.

Statistical Information

Confidence Interval

95% CI 3.57–6.34 for central obesity; 95% CI 1.11–3.45 for diabetes; 95% CI 1.01–2.03 for hyperlipidaemia; 95% CI 5.49–17.59 for impaired kidney function.

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s00394-024-03532-6

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication